Recent Trends in Drug Development and Clinical Trials for Hyperuricemia: A Pharmaprojects-Based Landscape Analysis

Hyperuricemia is increasingly prevalent and is closely associated with gout and several cardiometabolic and renal disorders. Although pharmacological development in this field is expanding, the overall structure and recent evolution of the global development pipeline remain incompletely characterized. This study aimed to characterize recent trends in drug development and clinical research for hyperuricemia.

Hyperuricemia-related drug-development records were retrieved from the Pharmaprojects database from database inception to July 31, 2025. Records were screened according to disease classification, pharmacological relevance, and development status. After screening and data verification, 69 eligible records were included. Development stage, geographical distribution, therapeutic class, mechanism of action, molecular target, and commencement date were analyzed descriptively.

A total of 69 eligible drug-development records were included. The pipeline was predominantly concentrated in preclinical and early clinical development, with preclinical programs accounting for 31.88%, Phase I for 20.29%, Phase II for 18.84%, and Phase III for 17.39%. China and the United States represented important contributors to the identified development activities. The development portfolio was dominated by gout-related therapies but showed increasing mechanistic diversity. URAT1-related approaches were prominent, and SLC22A12 was the most frequently represented molecular target. Xanthine oxidase-, uricase-, and inflammation-related mechanisms were also represented.

The global development pipeline for hyperuricemia remains weighted toward preclinical and early clinical stages but is becoming increasingly diverse in therapeutic mechanisms and molecular targets. Further late-stage clinical evaluation, multicenter studies, and long-term safety assessment are required to establish the clinical value of emerging therapeutic strategies.